Cefepime microbiologic profile and update

Pediatric Infectious Disease Journal

Volumn 20, Issue 3, 2001, Pages 331-336

  Kessler, R E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cefepime; Fourth generation cephalosporin; Microbiologic profile

Indexed keywords

AMPHOLYTE; BETA LACTAMASE; CEFEPIME; CEPHALOSPORIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BINDING AFFINITY; CITROBACTER FREUNDII; DRUG STRUCTURE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; ENTEROBACTERIACEAE; HUMANS; PSEUDOMONAS AERUGINOSA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035079525     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200103000-00031     Document Type: Review

References (44)

1. The cephalosporins: Symposium on Antimicrobial Agents, Part V
2. Fourth-generation cephalosporins
3. Cefepime
4. Cefepime: A fourth-generation parenteral cephalosporin
5. Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period
6. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model
7. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods
8. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States
9. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
10. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the E-test
11. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the E-test method
12. Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the E-test method
13. Multicenter study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of Gram-positive and Gram-negative bacteria from hospitalized patients in Switzerland
14. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum beta-lactams in Turkey using the E-test method
15. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2000 clinical isolates from 22 medical centers in Japan
16. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample
17. Comparative affinities for penicillin-binding proteins of multipolar ionic amphoteric cephalosporins in Gram-negative bacteria
18. Do we need fourth-generation cephalosporins?
19. Antibacterial in vitro activity of fourth generation cephalosporins
20. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents
21. Antimicrobial activity of cefepime tested against Bush Group 1 beta-lactamase producing strains resistant to ceftazidime
22. Beta-lactamases of Gram-negative bacteria: New challenges for new drugs
23. In vitro activity of fourth generation cephalosporins against enterobacteriaceae producing extended-spectrum beta-lactamases
24. Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams
25. Evidence for structural elasticity of class A beta-lactamases in the course of catalytic turnover of the novel cephalosporin cefepime
26. Selection and characterization of cefepime-resistant Gram-negative bacteria
27. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime
28. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin
29. Development of beta-lactam-resistant Enterobacter cloacae in mice
30. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species
31. Cefepime decrease the resistance of inducible Enterobacteriaceae
32. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients
33. Antibiotic policy: A toll for controlling resistance of hospital pathogens
34. Performance standards for antimicrobial susceptibility testing, Ninth information supplement. Approved standards
35. Cefepime vs. ceftazidime treatment of pyelonephritis: A European, randomized, controlled study of 300 pediatric cases
36. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children
37. Childhood community-acquired pneumonia
38. A new therapeutic option for the treatment of pneumonia
39. Treatment of community-acquired pneumonia in the elderly: The role of cefepime, a fourth-generation cephalosporin
40. Cost-effective analysis of cefepime compared with ceftazidime in intensive care unit patients with hospital-acquired pneumonia
41. Cefepime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
42. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics
43. Comparison of broth microdilution and E-test for susceptibility testing of Neisseria meningitidis